These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16275959)

  • 41. How audible is nursing's voice at policy level in the Ministry of Health?
    Brinkman A
    Nurs N Z; 2006 Sep; 12(8):22, 10. PubMed ID: 17059025
    [No Abstract]   [Full Text] [Related]  

  • 42. Private equity firms are invited to get involved with commissioning.
    Iacobucci G
    BMJ; 2013 Nov; 347():f6694. PubMed ID: 24193093
    [No Abstract]   [Full Text] [Related]  

  • 43. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The health of our nation - the future of our health system: the national expert commission on the move.
    Villeneuve M
    Nurs Leadersh (Tor Ont); 2011 Jan; 24(4):31-3. PubMed ID: 22273556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 46. Conflicts of Interest of Public Speakers at Meetings of the Anesthetic and Analgesic Drug Products Advisory Committee.
    McCoy MS; Pagán O; Donohoe G; Kanter GP; Litman RS
    JAMA Intern Med; 2018 Jul; 178(7):996-997. PubMed ID: 29710219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A plea for transparency in Canada's "new government".
    Hébert PC; Attaran A
    CMAJ; 2007 Feb; 176(5):601, 603. PubMed ID: 17287421
    [No Abstract]   [Full Text] [Related]  

  • 48. Corporate corruption of science--the case of chromium(VI).
    Egilman D; Scout
    Int J Occup Environ Health; 2006; 12(2):169-76. PubMed ID: 16722197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vioxx should be allowed back on the market advises expert panel.
    Sibbald B
    CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435
    [No Abstract]   [Full Text] [Related]  

  • 50. Responsible interrogation.
    Nature; 2009 May; 459(7245):300. PubMed ID: 19458664
    [No Abstract]   [Full Text] [Related]  

  • 51. CMS Hospice Expert Panel shares top 10 hospice deficiencies.
    Neigh JE
    Caring; 2008 Aug; 27(8):60-1. PubMed ID: 18795539
    [No Abstract]   [Full Text] [Related]  

  • 52. Use of a dissector to facilitate breast implant removal and capsulectomy.
    Salgarello M; Cervelli D; Barone-Adesi L
    Ann Plast Surg; 2008 Jul; 61(1):122. PubMed ID: 18580162
    [No Abstract]   [Full Text] [Related]  

  • 53. Canada's new toxic hit list called "inadequate".
    Mackay B
    CMAJ; 2007 Feb; 176(4):431-2. PubMed ID: 17296948
    [No Abstract]   [Full Text] [Related]  

  • 54. Policy decision-making under scientific uncertainty: radiological risk assessment and the role of expert advisory groups.
    Mossman KL
    Health Phys; 2009 Aug; 97(2):101-6. PubMed ID: 19590269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guidelines on the use of intravenous immune globulin for hematologic conditions.
    Anderson D; Ali K; Blanchette V; Brouwers M; Couban S; Radmoor P; Huebsch L; Hume H; McLeod A; Meyer R; Moltzan C; Nahirniak S; Nantel S; Pineo G; Rock G
    Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S9-56. PubMed ID: 17397769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Getting serious about the social determinants of health: new directions for public health workers.
    Raphael D
    Promot Educ; 2008 Sep; 15(3):15-20. PubMed ID: 18784048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On bias and transparency in the development of influential recommendations.
    Laupacis A
    CMAJ; 2006 Jan; 174(3):335-6. PubMed ID: 16446476
    [No Abstract]   [Full Text] [Related]  

  • 58. Editorial.
    Aschner M; Autrup HN; Cohen SM; Dekant W; Eisenbrand G; Galli CL; Gori GB; Kaminski NE; Klaassen CD; Klaunig JE; Levy L; Lotti M; Marquardt HW; Pelkonen O; Schrenk DF; Yamazaki H
    Regul Toxicol Pharmacol; 2019 Feb; 101():A1-A2. PubMed ID: 30642615
    [No Abstract]   [Full Text] [Related]  

  • 59. Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
    Caulfield T
    Health Law Rev; 2005; 13(2-3):114-6. PubMed ID: 16459424
    [No Abstract]   [Full Text] [Related]  

  • 60. Up in smoke, what role should litigation play in funding Canada's health care.
    Berryman J
    Health Law J; 2004; 12():125-57. PubMed ID: 16539079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.